Jing Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jing Sun has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Fuquan Zhang
Department of Psychiatry, the Affiliated Brain Hospital of Nanjing Medical University
2 shared publications Hongbao Cao
School of Systems Biology, George Mason University, Manassas, USA
2 shared publicationsAncha Baranova
School of Systems Biology, George Mason University, Manassas, USA
1 shared publication- Ancha Baranova
School of Systems Biology, George Mason University, Fairfax, VA, USA; Research Centre for Medical Genetics, Moscow, Russia
1 shared publication Cong-Rong Li
State Key Lab of Reproductive Medicine, Nanjing Medical University, Nanjing, 211166 Jiangsu, China
1 shared publication- Dong Zhang
The First Affiliated Hospital of Anhui Medical University
1 shared publication
Latest Publications
- Open Access
- 3 November 2026
- Published by Springer Nature in BMC Psychiatry
Gonadal and thyroid hormone profiles in women with hormone-sensitive bipolar disorder: an exploratory cross-sectional study
- 3 November 2026
- Published by Springer Nature in BMC Psychiatry
Open AccessGonadal and thyroid hormone profiles in women with hormone-sensitive bipolar disorder: an exploratory cross-sectional study
- Open Access
- 1 July 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 25 (1) , 1-10
Sex differences in lithium concentrations among bipolar patients with different episodes based on real-world therapeutic monitoring data
Sex differences in lithium-associated efficacy and adverse events have been well studied in bipolar disorder. Exploring variations in lithium concentrations between sexes may offer potential explanations. This multicenter, real-world, observational study, which was based on therapeutic monitoring data, was conducted at six Chinese hospitals. Sex differences in lithium concentrations and potential affecting factors were explored using the generalized estimating equation and multiple linear regression analysis, respectively. A total of 525 bipolar patients were included, comprising 328 patients diagnosed with mania or mania with depressive features and 197 with bipolar depression. There were 398 females and 127 males, including 79 patients aged 13–17 years. The median final lithium dosage of all the subjects was 0.9 g per day, with an average final concentration of 0.68 mmol/L. The lithium concentration was relatively stable in the context of a fixed dosage. In patients with mania or mixed features, lithium concentrations in females were significantly higher than those in males when a fixed lithium dosage was administered. This phenomenon was not observed in patients with bipolar depression. The number of factors influencing lithium concentrations was greater for males with mania or mixed features than for females, which was not observed between males and females with bipolar depression. The therapeutic lithium concentrations of bipolar male and female patients in real-world clinical practice were lower than the guideline-recommended ranges. In patients with manic or mixed features, females have a greater propensity for lithium accumulation than males do, and lithium concentrations are more likely to be affected by internal and external changes in males than in females. Therefore, the potential risk of toxicity and the stability of lithium concentrations are key points in females and males on lithium therapy, respectively.
- 1 July 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 25 (1) , 1-10
Open AccessSex differences in lithium concentrations among bipolar patients with different episodes based on real-world therapeutic monitoring data
Sex differences in lithium-associated efficacy and adverse events have been well studied in bipolar disorder. Exploring variations in lithium concentrations between sexes may offer potential explanations. This multicenter, real-world, observational study, which was based on therapeutic monitoring data, was conducted at six Chinese hospitals. Sex differences in lithium concentrations and potential affecting factors were explored using the generalized estimating equation and multiple linear regression analysis, respectively. A total of 525 bipolar patients were included, comprising 328 patients diagnosed with mania or mania with depressive features and 197 with bipolar depression. There were 398 females and 127 males, including 79 patients aged 13–17 years. The median final lithium dosage of all the subjects was 0.9 g per day, with an average final concentration of 0.68 mmol/L. The lithium concentration was relatively stable in the context of a fixed dosage. In patients with mania or mixed features, lithium concentrations in females were significantly higher than those in males when a fixed lithium dosage was administered. This phenomenon was not observed in patients with bipolar depression. The number of factors influencing lithium concentrations was greater for males with mania or mixed features than for females, which was not observed between males and females with bipolar depression. The therapeutic lithium concentrations of bipolar male and female patients in real-world clinical practice were lower than the guideline-recommended ranges. In patients with manic or mixed features, females have a greater propensity for lithium accumulation than males do, and lithium concentrations are more likely to be affected by internal and external changes in males than in females. Therefore, the potential risk of toxicity and the stability of lithium concentrations are key points in females and males on lithium therapy, respectively.
- Open Access
- 1 October 2024
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 20, 2029-2037
Combined Predictors for the Diagnostic Transition from Acute and Transient Psychotic Disorder to Schizophrenia: A Retrospective Study
Purpose: Acute and transient psychotic disorder (ATPD), a psychosis frequently diagnosed, can potentially evolve into chronic conditions like schizophrenia (SCZ) and other mental disorders. This study aimed to develop a predictive model based on clinical data to forecast the transition from ATPD to SCZ and to identify the predictive factors. Methods: According to the diagnostic criteria issued by the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10), 396 inpatients diagnosed with ATPD were collected in this study. The Cox proportional-hazards regression model was performed using demographic data, clinical characteristics, and inflammatory markers to identify independent predictors for subsequent diagnostic transition (SDT) to SCZ. Results: During the follow-up period, 43.69% (n = 173) of ATPD patients had their diagnoses revised to SCZ. The multivariate Cox regression analysis identified post-treatment monocyte count, post-treatment monocyte/lymphocyte ratio (MLR), and the presence of schizophreniform symptoms as significant predictors for the diagnostic revision. Time-dependent receiver operating characteristic (TimeROC) analyses were developed. The AUC value at the 5-year follow-up was 0.728 for combined predictors, 0.702 for post-treatment monocyte count, 0.764 for post-treatment MLR, and 0.535 for the presence of schizophreniform symptoms. Conclusion: The combined predictors had good predictive ability for the diagnostic transition from acute and transient psychotic disorder to schizophrenia.
- 1 October 2024
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 20, 2029-2037
Open AccessCombined Predictors for the Diagnostic Transition from Acute and Transient Psychotic Disorder to Schizophrenia: A Retrospective Study
Purpose: Acute and transient psychotic disorder (ATPD), a psychosis frequently diagnosed, can potentially evolve into chronic conditions like schizophrenia (SCZ) and other mental disorders. This study aimed to develop a predictive model based on clinical data to forecast the transition from ATPD to SCZ and to identify the predictive factors. Methods: According to the diagnostic criteria issued by the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10), 396 inpatients diagnosed with ATPD were collected in this study. The Cox proportional-hazards regression model was performed using demographic data, clinical characteristics, and inflammatory markers to identify independent predictors for subsequent diagnostic transition (SDT) to SCZ. Results: During the follow-up period, 43.69% (n = 173) of ATPD patients had their diagnoses revised to SCZ. The multivariate Cox regression analysis identified post-treatment monocyte count, post-treatment monocyte/lymphocyte ratio (MLR), and the presence of schizophreniform symptoms as significant predictors for the diagnostic revision. Time-dependent receiver operating characteristic (TimeROC) analyses were developed. The AUC value at the 5-year follow-up was 0.728 for combined predictors, 0.702 for post-treatment monocyte count, 0.764 for post-treatment MLR, and 0.535 for the presence of schizophreniform symptoms. Conclusion: The combined predictors had good predictive ability for the diagnostic transition from acute and transient psychotic disorder to schizophrenia.
- Open Access
- 2 September 2024
- Published by Springer Nature in Schizophrenia
- Vol. 10 (1) , 1-6
Gut microbiome and schizophrenia: insights from two-sample Mendelian randomization
Growing evidence suggests a potential link between the gut microbiome and schizophrenia. However, it is unclear whether the gut microbiome is causally associated with schizophrenia. We performed two-sample bidirectional Mendelian randomization to detect bidirectional causal relationships between gut microbiome and schizophrenia. Summary genome-wide association study (GWAS) datasets of the gut microbiome from the MiBioGen consortium (n = 18,340) and schizophrenia (n = 130,644) were utilized in our study. Then a cohort of sensitive analyses was followed to validate the robustness of MR results. We identified nine taxa that exerted positive causal effects on schizophrenia (OR: 1.08–1.16) and six taxa that conferred negative causal effects on schizophrenia (OR: 0.88–0.94). On the other hand, the reverse MR analysis showed that schizophrenia may increase the abundance of nine taxa (OR: 1.03–1.08) and reduce the abundance of two taxa (OR: 0.94). Our study unveiled mutual causal relationships between gut microbiome and schizophrenia. The findings may provide evidence for the treatment potential of gut microbiomes in schizophrenia.
- 2 September 2024
- Published by Springer Nature in Schizophrenia
- Vol. 10 (1) , 1-6
Open AccessGut microbiome and schizophrenia: insights from two-sample Mendelian randomization
Growing evidence suggests a potential link between the gut microbiome and schizophrenia. However, it is unclear whether the gut microbiome is causally associated with schizophrenia. We performed two-sample bidirectional Mendelian randomization to detect bidirectional causal relationships between gut microbiome and schizophrenia. Summary genome-wide association study (GWAS) datasets of the gut microbiome from the MiBioGen consortium (n = 18,340) and schizophrenia (n = 130,644) were utilized in our study. Then a cohort of sensitive analyses was followed to validate the robustness of MR results. We identified nine taxa that exerted positive causal effects on schizophrenia (OR: 1.08–1.16) and six taxa that conferred negative causal effects on schizophrenia (OR: 0.88–0.94). On the other hand, the reverse MR analysis showed that schizophrenia may increase the abundance of nine taxa (OR: 1.03–1.08) and reduce the abundance of two taxa (OR: 0.94). Our study unveiled mutual causal relationships between gut microbiome and schizophrenia. The findings may provide evidence for the treatment potential of gut microbiomes in schizophrenia.
- Open Access
- 1 January 2022
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 2022
ATP5O Hypo-crotonylation Caused by HDAC2 Hyper-Phosphorylation Is a Primary Detrimental Factor for Downregulated Phospholipid Metabolism under Chronic Stress
Objective. Chronic stress (CS)-induced abnormal metabolism and other subsequent aspects of abnormality are threatening human health. Little is known regarding whether and how protein post-translational-modifications (PTMs) correlate with abnormal metabolism under CS. The aim of this study was to address this issue and also identify novel key protein PTM. Methods. First, we screened which pan-PTM had significant change between control and CS female mice and whether clinical CS females had similar pan-PTM change. Second, we performed quantitative PTM-omics and metabolomics to verify the correlation between abnormal protein PTMs and atypical metabolism. Third, we performed quantitative phospho-omics to identify the key PTM-regulating enzyme and investigate the interaction between PTM protein and PTM-regulating enzyme. Fourth, we attempted to rectify the abnormal metabolism by correcting the activity of the PTM-regulating enzyme. Finally, we examined whether the selected key protein was also correlated with stress scores and atypical metabolism in clinical women. Results. We initially found that multiple tissues of CS female mice have downregulated pan-crotonylation, and verified that the plasma of clinical CS females also had downregulated pan-crotonylation. Then we determined that ATP5O-K51 crotonylation decreased the most and also caused gross ATP5O decrement, whereas the plasma of CS mice had downregulated phospholipids. Next, downregulating ATP5O crotonylation partially recapitulated the downregulated phospholipid metabolism in CS mice. Next, we verified that HDAC2-S424 phosphorylation determined its decrotonylation activity on ATP5O-K51. Furthermore, correcting HDAC2 hyper-phosphorylation recovered the gross ATP5O level and partially rescued the downregulated phospholipid metabolism in CS mice. Finally, the ATP5O level was also significantly lower and correlated with high stress scores and downregulated phospholipid metabolism in clinical female plasma. Conclusion. This study discovered a novel PTM mechanism involving two distinct types of PTM in CS and provided a novel reference for the clinical precautions and treatments of CS.
- 1 January 2022
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 2022
Open AccessATP5O Hypo-crotonylation Caused by HDAC2 Hyper-Phosphorylation Is a Primary Detrimental Factor for Downregulated Phospholipid Metabolism under Chronic Stress
Objective. Chronic stress (CS)-induced abnormal metabolism and other subsequent aspects of abnormality are threatening human health. Little is known regarding whether and how protein post-translational-modifications (PTMs) correlate with abnormal metabolism under CS. The aim of this study was to address this issue and also identify novel key protein PTM. Methods. First, we screened which pan-PTM had significant change between control and CS female mice and whether clinical CS females had similar pan-PTM change. Second, we performed quantitative PTM-omics and metabolomics to verify the correlation between abnormal protein PTMs and atypical metabolism. Third, we performed quantitative phospho-omics to identify the key PTM-regulating enzyme and investigate the interaction between PTM protein and PTM-regulating enzyme. Fourth, we attempted to rectify the abnormal metabolism by correcting the activity of the PTM-regulating enzyme. Finally, we examined whether the selected key protein was also correlated with stress scores and atypical metabolism in clinical women. Results. We initially found that multiple tissues of CS female mice have downregulated pan-crotonylation, and verified that the plasma of clinical CS females also had downregulated pan-crotonylation. Then we determined that ATP5O-K51 crotonylation decreased the most and also caused gross ATP5O decrement, whereas the plasma of CS mice had downregulated phospholipids. Next, downregulating ATP5O crotonylation partially recapitulated the downregulated phospholipid metabolism in CS mice. Next, we verified that HDAC2-S424 phosphorylation determined its decrotonylation activity on ATP5O-K51. Furthermore, correcting HDAC2 hyper-phosphorylation recovered the gross ATP5O level and partially rescued the downregulated phospholipid metabolism in CS mice. Finally, the ATP5O level was also significantly lower and correlated with high stress scores and downregulated phospholipid metabolism in clinical female plasma. Conclusion. This study discovered a novel PTM mechanism involving two distinct types of PTM in CS and provided a novel reference for the clinical precautions and treatments of CS.